Elutia Inc.

Elutia Inc. is a commercial-stage regenerative medicine company dedicated to developing and commercializing differentiated products that enhance outcomes for patients undergoing surgery, particularly those receiving implantable medical devices. The company's core mission is to humanize medicine, enabling patients to thrive without compromise by addressing the persistent challenges associated with traditional medical implants through the integration of drugs, biologics, and advanced science. Headquartered in Gaithersburg, Maryland, Elutia focuses on pioneering next-generation drug-eluting biomaterial platforms.

Elutia's product portfolio leverages a proprietary drug-eluting biomaterial platform that fuses biologic material with extended antibiotic release, optimized for device implantation and soft tissue reconstruction. Key products include the EluPro BioEnvelope, CanGaroo BioEnvelope (and its advanced version, CanGarooRM), and SimpliDerm for soft tissue repair. The company also offers cardiovascular products such as ProxiCor PC, ProxiCor CTR, Tyke, and VasCure VR. Elutia operates across several market segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment being a significant revenue driver.

Led by President & CEO C. Randal Mills, Ph.D., Elutia has recently undergone significant strategic developments. In September 2025, the company announced the sale of its BioEnvelope business, including EluPro and CanGaroo bioenvelopes, to Boston Scientific Corporation for $88 million, a move intended to fund the advancement of its NXT-41x program for breast reconstruction. In March 2026, Elutia reported its fourth-quarter and full-year 2025 financial results, initiating the regulatory process for NXT-41 with anticipated FDA clearance in the second half of 2026, and full NXT-41x clearance expected in the first half of 2027. The company also appointed Pete Ligotti as Chief Commercial Officer in March 2026 to spearhead the commercial launch of NXT-41x, targeting the $1.5 billion U.S. breast surgery market.